^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LBA18 - POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)
Published date:
09/13/2021
Excerpt:
Addition of taselisib to TAM increased median PFS from 3.2 to 4.8m (unstratified HR 0.62, 95%CI 0.43-0.93, p=0.02; stratified HR 0.68, 95%CI 0.4-1.2, p=0.16)...In taselisib arm, ORR 11.8% (95%CI 5.6- 21.3) and CBR 22.4% (95%CI 13.6-33.4); in PLA arm, ORR 2.6% (95%CI 0.3- 9.2) and CBR 14.5% (95%CI 7.5-24.4)….Addition of taselisib to TAM increased PFS in pts with HR+/HER2-neg MBC...
Secondary therapy:
tamoxifen
Trial ID:
